Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 114,746 Shares

Posted by Francis Steltz on Jun 23rd, 2026

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider David Kirn sold 114,746 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the sale, the insider owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Kirn also recently made the following trade(s):

On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Price Performance

FDMT traded up $1.18 during trading on Tuesday, hitting $11.60. 2,067,737 shares of the stock traded hands, compared to its average volume of 784,497. 4D Molecular Therapeutics, Inc. has a twelve month low of $3.68 and a twelve month high of $12.34. The company has a market cap of $606.45 million, a price-to-earnings ratio of -4.51 and a beta of 2.75. The business has a 50 day moving average price of $9.44 and a 200 day moving average price of $9.12.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on FDMT. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. Finally, The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.88.

View Our Latest Analysis on 4D Molecular Therapeutics

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its holdings in shares of 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after buying an additional 2,882,508 shares in the last quarter. State Street Corp increased its stake in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. RA Capital Management L.P. lifted its position in shares of 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of 4D Molecular Therapeutics by 605.8% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after acquiring an additional 1,060,156 shares during the period. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at $7,136,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.